

A non-interventional biomarker study in patients with Non-Small Cell Lung Cancer (NSCLC) of adenocarcinoma tumour histology eligible for treatment with Vargatef® according to the approved label (LUME BioNIS)

First published: 22/01/2016

Last updated: 18/09/2020

Study

Finalised

Administrative details

EU PAS number

EUPAS11885

Study ID

37252

DARWIN EU® study

No

Study countries

- Austria
- Belgium
- Denmark
- Germany
- Greece
- Hungary
- Italy
- Lithuania
- Luxembourg
- Netherlands
- Spain
- Sweden
- United Kingdom

Study description

To explore whether genetic/genomic markers (alone or combined with clinical covariates) could be used to predict overall survival (OS) in NSCLC patients eligible for treatment with Vargatef® according to the approved label.

Study status

Finalised

Research institutions and networks

Institutions

Multiple centres: 71 centres are involved in the study

Contact details

Study institution contact

Boehringer Ingelheim clintriage.rdg@boehringer-ingelheim.com

[Study contact](#)

clintriage.rdg@boehringer-ingelheim.com

Primary lead investigator

Martin Reck

[Primary lead investigator](#)

Study timelines

Date when funding contract was signed

Actual: 12/06/2015

Study start date

Planned: 09/03/2016

Actual: 09/03/2016

Data analysis start date

Planned: 01/11/2019

Actual: 14/03/2016

Date of final study report

Planned: 30/06/2020

Actual: 08/07/2020

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Boehringer Ingelheim

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Other

If 'other', further details on the scope of the study

Biomarker assessment

Data collection methods:

Primary data collection

Main study objective:

Overall Survival in relation to exploratory biomarker assessment, including gene-expressions and genomic alterations.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name

VARGATEF

Medical condition to be studied

Non-small cell lung cancer stage IIIB

Population studied

Short description of the study population

NSCLC patients eligible for treatment with Vargatef®.

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Non-small cell lung cancer patients

Estimated number of subjects

260

Study design details

Outcomes

Overall Survival, Disease progression

Data analysis plan

Biomarkers will be investigated by univariate and multivariate prediction models and regression analysis. For all univariate screening approaches, multiplicity correction of p-values will be performed. Model performances will be quantified and uncertainty will be evaluated by resampling methods. Categorical biomarkers will only be investigated provided there are sufficient patient numbers within the subgroups defined by the categorical biomarkers. For all

selected categorical biomarkers the estimate of the HR/odds ratio and its 95% confidence interval (CI) will be presented. For continuous biomarkers the HR/odds ratio for a change per unit will be presented.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No